Swiss National Bank raised its holdings in Teladoc, Inc. (NYSE:TDOC) by 4.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 59,500 shares of the health services provider’s stock after acquiring an additional 2,700 shares during the period. Swiss National Bank owned 0.11% of Teladoc worth $2,065,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Bank of Montreal Can raised its holdings in Teladoc by 214.2% in the 2nd quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after acquiring an additional 2,397 shares during the last quarter. Pacad Investment Ltd. acquired a new position in Teladoc in the 2nd quarter valued at $135,000. Great West Life Assurance Co. Can acquired a new position in Teladoc in the 1st quarter valued at $105,000. US Bancorp DE raised its holdings in Teladoc by 10.3% in the 1st quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock valued at $116,000 after acquiring an additional 433 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in Teladoc by 66.3% in the 1st quarter. Legal & General Group Plc now owns 6,137 shares of the health services provider’s stock valued at $154,000 after acquiring an additional 2,446 shares during the last quarter.

WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/10/05/swiss-national-bank-has-2-07-million-holdings-in-teladoc-inc-tdoc.html.

Shares of Teladoc, Inc. (NYSE TDOC) opened at 34.80 on Thursday. The stock’s market capitalization is $1.97 billion. The stock’s 50 day moving average is $33.26 and its 200 day moving average is $33.26. Teladoc, Inc. has a 52 week low of $14.00 and a 52 week high of $37.55.

Teladoc (NYSE:TDOC) last released its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $44.60 million during the quarter, compared to analysts’ expectations of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The firm’s quarterly revenue was up 68.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.38) EPS. Analysts anticipate that Teladoc, Inc. will post ($1.44) EPS for the current fiscal year.

In other news, VP Mark Hirschhorn sold 10,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $34.04, for a total transaction of $340,400.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Adam C. Vandervoort sold 53,806 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the transaction, the insider now owns 33,008 shares in the company, valued at approximately $1,020,607.36. The disclosure for this sale can be found here. Insiders have sold a total of 108,806 shares of company stock worth $3,471,732 in the last 90 days. 4.47% of the stock is owned by insiders.

Several research analysts have weighed in on TDOC shares. Cowen and Company reiterated an “outperform” rating and issued a $39.00 price target (up from $36.00) on shares of Teladoc in a report on Thursday, August 3rd. Piper Jaffray Companies reissued a “buy” rating and set a $32.00 price objective on shares of Teladoc in a research note on Friday, July 14th. TheStreet cut shares of Teladoc from a “c-” rating to a “d” rating in a research note on Monday, July 3rd. BidaskClub cut shares of Teladoc from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Finally, William Blair reissued an “outperform” rating on shares of Teladoc in a research note on Tuesday, June 20th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $38.00.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Institutional Ownership by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.